Viridian Therapeutics grants options to director Ajer

Viridian Therapeutics director Jeffrey Robert Ajer received a grant of stock options for 32,341 shares of common stock at an exercise price of $18.48 per share.

Rhea-AI Filing Summary

Viridian Therapeutics director Jeffrey Robert Ajer received a grant of stock options for 32,341 shares of common stock at an exercise price of $18.48 per share. These options were awarded as compensation and give him the right to buy shares in the future at that fixed price. The options vest in full on the earlier of July 1, 2027 or the company’s 2027 annual meeting of stockholders, if he continues serving on the board until that time. After this grant, he holds stock options covering 32,341 underlying shares directly.

Insider Trade Summary

Grant/Award: 32,341 shares

Grant/Award 1 txn

Insider Ajer Jeffrey Robert

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	32,341	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 32,341 contracts (Direct)

Footnotes (1)

1. F1. The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.

Key Figures

Option grant size: 32,341 options Underlying shares: 32,341 shares Exercise price: $18.48 per share +3 more

6 metrics

Option grant size 32,341 options Stock Option (Right to Buy) granted to director

Underlying shares 32,341 shares Common Stock underlying the option grant

Exercise price $18.48 per share Conversion or exercise price of stock options

Expiration date July 1, 2036 Option expiration for the granted stock options

Post-grant derivative holdings 32,341 options Total shares following transaction (derivative)

Vesting condition date July 1, 2027 Latest vesting date, or earlier 2027 annual meeting

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, annual meeting of stockholders, +1 more

5 terms

Stock Option (Right to Buy) financial

"The security is described as a "Stock Option (Right to Buy)" with underlying common shares."

exercise price financial

"The option has a conversion or exercise price of $18.48 per share."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"The option carries an expiration date of July 1, 2036 for exercising rights."

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

annual meeting of stockholders financial

"The option vests by July 1, 2027 or the Issuer's 2027 annual meeting of stockholders."

Board of Directors financial

"Vesting is subject to the Reporting Person's continued service on the Board of Directors."

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Viridian Therapeutics (VRDN) report for Jeffrey Robert Ajer?

Viridian reported that director Jeffrey Robert Ajer received a grant of stock options for 32,341 shares of common stock. These options were awarded at a fixed exercise price of $18.48 per share as part of his compensation for board service.

How many Viridian Therapeutics (VRDN) shares are covered by the new stock option grant?

The new stock option grant covers 32,341 underlying shares of Viridian Therapeutics common stock. This full amount represents Ajer’s post-transaction derivative holdings from this grant, giving him the right to acquire those shares if he exercises the options.

What is the exercise price of Jeffrey Robert Ajer’s Viridian Therapeutics (VRDN) stock options?

The exercise price of the stock options granted to Jeffrey Robert Ajer is $18.48 per share. This price is the fixed cost he would pay per share to convert the options into Viridian Therapeutics common stock in the future.

When do Jeffrey Robert Ajer’s Viridian Therapeutics (VRDN) stock options vest?

The options vest in full on the earlier of July 1, 2027 or Viridian Therapeutics’ 2027 annual meeting of stockholders. Vesting is conditional on his continued service on the company’s board of directors through that date or event.

What is the expiration date of the Viridian Therapeutics (VRDN) stock options granted to Ajer?

The stock options granted to Jeffrey Robert Ajer expire on July 1, 2036. After that expiration date, any unexercised options will lapse, and he will no longer have the right to purchase Viridian Therapeutics common shares under this grant.

Is the Viridian Therapeutics (VRDN) Form 4 transaction a purchase or a grant?

The Form 4 transaction is a grant of stock options, not an open-market share purchase. It is coded as an “A” transaction, reflecting a grant or award acquisition of derivative securities as compensation for board service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/02/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ajer Jeffrey Robert

(Last) (First) (Middle)

C/O VIRIDIAN THERAPEUTICS, INC.

221 CRESCENT STREET, SUITE 103A

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Viridian Therapeutics, Inc.\DE [ VRDN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$18.48	07/01/2026		A		32,341		(1)	07/01/2036	Common Stock	32,341	$0.00	32,341	D

Explanation of Responses:

1. The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.

	/s/ Jennifer Tousignant, Attorney-in-fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)